Tuesday, April 28, 2026, 12:00 PM–1:00 PM ET
Discover how next-day comprehensive genomic profiling (CGP) is possible with the Oncomine Comprehensive Assay Plus on the Genexus System—delivering both speed and accuracy.
Webinar presenters Jane Bayani, MHSc, PhD, Assistant Professor and Co-Director, Diagnostic Development, Ontario Institute for Cancer Research, Canada, and Nicola Normanno, MD, Scientific Director, IRCCS Romagnolo Institute for the Study of Tumors, Italy, and Morten Grauslund, PhD, Molecular Biologist, Department of Pathology, Rigshospitalet/Copenhagen University Hospital, Copenhagen, Denmark.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Thermo Fisher Scientific. For Research Use Only. Not for use in diagnostic applications.
Thursday, April 30, 2026, 11:00 AM–12:00 PM ET
Hear an expert discuss how Memorial Sloan Kettering Cancer Center (MSKCC) is utilizing
the oncoReveal® Nexus 21-gene panel to redefine turnaround time and actionable insights
in cancer care. Dr. Ewalt shares a perceptive look at the clinical need for rapid, front-line NGS sequencing, and how a unique, purpose built targeted NGS panel (Pillar Biosciences’ oncoReveal Nexus 21 gene Panel) was developed, validated and implemented clinically by Memorial Sloan Kettering Cancer Center (MSK-REACT) to complement their current comprehensive genomic profiling (CGP) approach.
Webinar presenter Mark Ewalt, MD, Associate Medical Director for Laboratory Operations for Diagnostic Molecular Pathology in the Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, MSKCC.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Pillar Biosciences.
Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
April 20, 2026—PathAI and MedStar Health announced a multiyear strategic collaboration to deploy PathAI’s AISight Dx digital pathology platform and AI algorithm products, including PathAI’s ArtifactDetect and TumorDetect, across MedStar’s network.
April 16, 2026—Labcorp launched the Labcorp Fentanyl Urine Visual Test.
April 15, 2026—Streck released MDx-Chex for RLP, a ready-to-use, full-process molecular quality control designed for respiratory low-plex assay verification.
April 10, 2026—Telcor has acquired Sample Healthcare, an AI workflow platform designed to execute revenue cycle and clinical operations workflows.
April 1, 2026—Streck has launched MDx-Chex for CT/NG/TV and MDx-Chex for MVP (multiplex vaginal panel) controls for research use only.
March 31, 2026—The Food and Drug Administration granted 510(k) clearance to Roche’s Cobas c 703 and Cobas ISE Neo analytical units.
March 24, 2026—Leica Biosystems launched in the U.S. the Aperio GT Elite scanner and Aperio iQC software.
March 20, 2026—Siemens Healthineers has launched the Atellica IM Phosphorylated tau 217 and Atellica IM Brain Derived Tau assays for research use.
March 18, 2026—Roche received CLIA moderate complexity categorization for its Ionify steroid assays for mass spectrometry.
March 13, 2026—The Food and Drug Administration has cleared the Qiagen QIAstat-Dx Gastrointestinal Panel 2 and QIAstat-Dx GI Panel 2 Mini B and Mini B&V for use on the QIAstat-Dx Rise automated syndromic testing system.
